Date published: 2025-11-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

TP53TG3 Activators

TP53TG3, also known as TP53 Target 3, is a gene that is transcriptionally regulated by the tumor suppressor protein p53. This gene is part of a network of p53-responsive genes that play critical roles in mediating the cellular response to stress and DNA damage. Specifically, TP53TG3 has been implicated in the processes of cell cycle arrest and apoptosis, which are vital mechanisms by which cells prevent the propagation of damage that could lead to tumorigenesis. The protein encoded by TP53TG3 is believed to function within these pathways, helping to maintain genomic stability and prevent malignant transformation. The activation of TP53TG3, therefore, is crucial for the p53 tumor suppressor pathway, serving as a downstream effector that helps to execute the cell's response to genotoxic stress. This includes initiating repair mechanisms or triggering cell death in cases where damage is too extensive, thereby contributing to the suppression of tumor development and progression.

The activation of TP53TG3 is tightly controlled and predominantly occurs in response to signals that activate p53, such as DNA damage, oxidative stress, and oncogene activation. When p53 is activated, it can directly bind to the promoter region of the TP53TG3 gene, stimulating its transcription. This transcriptional activation is a key aspect of the p53 response, leading to an increase in TP53TG3 protein levels following stress signals. Additionally, the activity and stability of the TP53TG3 protein may be regulated by post-translational modifications, which could affect its interaction with other proteins involved in the apoptosis and cell cycle arrest pathways. For example, phosphorylation or ubiquitination could alter the functional capacity of TP53TG3, modulating its role in these critical cellular processes. The regulation of TP53TG3 by p53 not only underscores the gene's importance in stress and damage responses but also highlights the complexity of the pathways that govern cellular responses to abnormalities, ensuring that such responses are precisely timed and appropriately scaled in relation to the level of stress or damage experienced by the cell.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Nutlin-3

548472-68-0sc-45061
sc-45061A
sc-45061B
1 mg
5 mg
25 mg
$56.00
$212.00
$764.00
24
(1)

MDM2 inhibitor, thus stabilizing TP53 and can enhance the TP53 pathway, leading to increased expression of TP53TG3.

Fluorouracil

51-21-8sc-29060
sc-29060A
1 g
5 g
$36.00
$149.00
11
(1)

DNA damaging agent, activating the TP53 pathway which can subsequently increase TP53TG3 expression.

Actinomycin D

50-76-0sc-200906
sc-200906A
sc-200906B
sc-200906C
sc-200906D
5 mg
25 mg
100 mg
1 g
10 g
$73.00
$238.00
$717.00
$2522.00
$21420.00
53
(3)

DNA intercalating agent, stimulating the TP53 pathway, potentially upregulating TP53TG3.

Doxorubicin

23214-92-8sc-280681
sc-280681A
1 mg
5 mg
$173.00
$418.00
43
(3)

DNA intercalator that promotes TP53 pathway activity, which may enhance TP53TG3 expression.

Etoposide (VP-16)

33419-42-0sc-3512B
sc-3512
sc-3512A
10 mg
100 mg
500 mg
$32.00
$170.00
$385.00
63
(1)

Topoisomerase II inhibitor that can induce DNA damage, activating TP53 pathway, and possibly increasing TP53TG3 expression.

Cisplatin

15663-27-1sc-200896
sc-200896A
100 mg
500 mg
$76.00
$216.00
101
(4)

DNA crosslinking agent, inducing the TP53 pathway, which may lead to increased TP53TG3 levels.

Camptothecin

7689-03-4sc-200871
sc-200871A
sc-200871B
50 mg
250 mg
100 mg
$57.00
$182.00
$92.00
21
(2)

Topoisomerase I inhibitor, inducing DNA damage and activating TP53 pathway, potentially affecting TP53TG3 expression.

Tenovin-6

1011557-82-6sc-224296
sc-224296A
1 mg
5 mg
$272.00
$1214.00
9
(1)

SIRT1 and SIRT2 inhibitor that can activate TP53, subsequently potentially enhancing TP53TG3 expression.

PRIMA-1

5608-24-2sc-200927
sc-200927A
5 mg
25 mg
$102.00
$408.00
1
(1)

Reactivates mutant TP53, leading to potential TP53 pathway activation and possible increase in TP53TG3 expression.